Skip to menu Skip to content Skip to footer
News

Detecting lung cancer with nanotech

9 July 2024
A close up image of a slide showing tiny rectangles, held up by the gloved hand of a researcher who is out of focus.
Quan Zhou holds up the device his laboratory is using to explore faster, more accurate methods of diagnosis. Image: The University of Queensland.

University of Queensland researchers have designed a device that uses a simple blood test to detect early stage lung cancer.

Dr Richard Lobb and Quan Zhou from UQ’s Australian Institute for Bioengineering and Nanotechnology said the diagnostic device could help patients begin treatment and get ahead of the disease before it spreads.

“Lung cancer is the most common cause of cancer death in Australia, claiming the lives of almost 9000 people each year,” Dr Lobb said.

“Despite its prevalence, the initial detection and screening process for the disease can be drawn out and expensive, involving scans, imaging tests and biopsy procedures.

“The technology we’ve developed is non-invasive and can detect very small lung cancer nodules to hopefully catch the disease in the first stage.”

The nanodevice analyses the patient’s blood sample, looking for a particular biomarker – the sugars that coat the tiny messenger particles known as extracellular vesicles (EVs).

Decorative
“These sugar molecules, or glycans, serve as excellent biomarkers because the sugar code on a cancer cell is different to a normal cell,” Dr Lobb said.

“A drop of blood can be all that’s needed to alert clinicians to the presence of small lung cancer nodules and allow intervention while the disease is in its early stages,” Dr Lobb said.

A clinical study involving 40 patients found the technology successfully differentiated patients with early-stage malignant lung nodules from those with benign lung nodules. 

“The results show the potential to use EV glycans to diagnose other diseases non-invasively,” Mr Zhou said.

“This device, and a simple blood test, could help clinicians step in before more intensive scanning or treatments or drug regimes are needed.” 

The nanodevice was designed in the lab of ARC Laureate and AIBN senior group leader Professor Matt Trau, with AIBN scholars Xueming Niu, Dr Alain Wuethrich and Dr Zhen Zhang contributing to the research.

The research paper was published in Advanced Science.  

Image above left: Dr Richard Lobb and Quan Zhou.  

Media contact

AIBN Communications
communications@aibn.uq.edu.au
+61 447 305 979

 

Related articles

Four cyclists gliding along in the sunrise at the Trapiche in Pelotas, Brazil.

Staying physically active cuts risk of early death by 40 per cent

Adults who stay consistently active throughout their life can lower their risk of early death by up to 40 per cent, a global study led by The University of Queensland has found.
11 July 2025
A droplet hovers on the end of a dropper over an open oil bottle, on a green and blue backdrop.
Analysis

Medicinal cannabis is big business. But the latest clampdown won’t curb unsafe prescribing

Australia’s key regulator of health professionals has announced it’s clamping down on unsafe prescribing of medicinal cannabis in the wake of surging patient demand.
10 July 2025

Media contact

Subscribe to UQ News

Get the latest from our newsroom.